GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?

SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG (“LimmaTech Bio”), a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, signed an in-license agreement with GlaxoSmithKline Biologicals SA (LSE/NYSE: GSK) enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio's predecessor company, GlycoVaxyn, was a.

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Patterson Companies

Perrigo

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

3 Healthcare Stocks to Buy Amid Market Volatility

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). GSK expects to distribute over 40 million doses of its influenza vaccine to the US market. Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in.

GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

Some legal headwinds from previous coverage have abated. GSK's usage estimate for Arexvy this year is likely on the low side. Two upcoming Prescription Drug User Fee Act action dates for other treatments occur in September.

GSK Rating Upgraded To Buy On New Earning Asset

SAN DIEGO--(BUSINESS WIRE)-- #mRNA--Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agreement with GSK plc (LSE/NYSE: GSK) to advance the discovery and development of Elsie's innovative oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery. The collaboration combines GSK's extensive expertise in DNA encoded library techn.

Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies

Compass Group PLC

Unilever

WPP Plc Sponsored

If a company is going to survive and thrive over many decades, it must focus on what it can do better than its peers. A flywheel may give a company an enduring competitive advantage that widens with each turn of the wheel. Quality dividend stocks focus on long-term success by applying the same basic growth strategy to reach the same long-term goal over many years and even decades.

How To Find Quality Dividend Stocks With Enduring Core Businesses

Britain's medicines regulator authorized GSK's vaccine for respiratory syncytial virus (RSV) for older adults, the drugmaker said on Monday.

UK regulator authorizes GSK's RSV vaccine

Bio-Techne

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?

GSK vs. TECH: Which Stock Is the Better Value Option?

Pfizer

The CDC said the shots from Pfizer and GSK are expected to be available this fall, when RSV – along with Covid and the flu – begins to spread at higher levels.

CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older

The director of the U.S. Centers for Disease Control and Prevention (CDC) signed off on Thursday on the use of new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults, the agency's spokesperson said.

US CDC recommends use of new Pfizer, GSK vaccines for RSV in older adults

Eli Lilly

Artificial intelligence is being used by the world's top drugmakers to speed up innovation in areas of high unmet medical need. GSK and Eli Lilly are both pioneers in the use of AI for drug discovery and development.

Better Artificial Intelligence Stock: GSK or Eli Lilly?

Like most stocks during the dot-com bubble, GSK PLC NYSE: GSK partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceutical company's market value.

Drugmaker GSK Is Becoming a Healthier Value Stock

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

GSK PLC (LSE:GSK, NYSE:GSK) has received fast-track designation from the US Food and Drug Administration (FDA) for its experimental vaccine against Neisseria gonorrhoeae, the bacteria causing gonorrhoea. As the name suggests, the status accelerates the drug's progress to approval.

GSK achieves fast-track Status from US regulator for groundbreaking gonorrhoea vaccine

GSK's vaccine candidate to treat sexually transmitted infection gonorrhoea has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Tuesday.

GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation

GSK has underperformed the broader markets and most of its big pharma peers over the last 10 years. With a tighter focus on branded pharma products, GSK arguably deserves another look by investors.

Is GSK a Strong Buy Right Now?

GSK PLC (LSE:GSK, NYSE:GSK)'s settlement with a California plaintiff over an alleged link between Zantac and cancer "clears 80%+ of the liability overhang", according to Jefferies. However, the US investment bank said that a risk "persists" because there are still other Zantac lawsuits pending.

GSK settlement clears much if the the Zantac liability 'overhang', says US bank

GSK, or GlaxoSmithKline, has performed badly in the past decade, but its future outlook may not be as bleak. The company has spun off its consumer healthcare segment to focus on the vaccine and HIV segments, which present huge growth opportunities. The current valuation is significantly discounted compared to both peers and its own historical average.

GSK: A Biopharma Giant On Sale

American depositary receipts of GSK jumped after the U.K.-based biopharma company said it had reached a settlement in a lawsuit accusing the firm's discontinued heartburn medicine, Zantac, of causing cancer.

GSK Settles Zantac Cancer Lawsuit Set to Go to Trial Next Month

GSK stock jumped Friday after the British drugmaker said it settled one of thousands of claims that its heartburn drug Zantac caused cancer.

GSK Surges After Settling First Zantac Case, But A 'Conveyor Belt' Of Claims Looms

CarMax

Markets opened lower on Friday. CarMax reported weak financial results that were nevertheless better than most investors had expected.

2 Stocks Defying Friday's Market Downturn

GSK PLC (LSE:GSK, NYSE:GSK) making an out-of-court settlement for a case in California alleging its Zantac heartburn medication caused cancer, is "not a full stop" for the saga, say analysts.  Paying an undisclosed amount to settle the lawsuit, which was filed in California by James Goetz and was scheduled for trial in July, "doesn't have any direct impact on other state level cases", said analyst Dr Sean Conroy at Shore Capita.

GSK out-of-court deal encouraging but 'not the final full stop' in Zantac saga, say analysts

GSK's settlement with a plaintiff in California over claims Zantac can cause cancer avoids a trial and brings it into line with industry peers.

News for GlaxoSmithKline Stock (GSK)